OakChart

Precigen Inc

PGENHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 3:59 PM ET

4.72+0.20 (4.42%)
2026-11-12 05:30 CET
Market cap
1,692.36 USD m
Revenue, TTM
156.94 USD m
Net income, TTM
24.41 USD m
Free cash flow, TTM
-74.32 USD m
EPS diluted, TTM
0.04
P/E
105.59
Compare

Price

PGEN against its 20, 50 and 200-day averages
2050200beatmissearnings
4.006.008.0013.3M26.6MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26PGENclose 4.7220-day 5.8150-day 6.84200-day 5.284.7252w high

47.4% under the 52-week high of 8.98 on 30 Sep 2026. 52-week low 3.04 on 25 Mar 2026. Last 15 sessions, 79.5% high to low

Volume 0.79× normal · the line is the 50-bar volume average

Profile

PGEN
52-week range, 28% of the way up
3.048.98

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

IndexRUT
Employees160
IPOAug 08, 2013
Beta1.04
ATR, 14d0.54
Rel volume0.79
Short float27.30%
Insider own54.13%
Inst own40.81%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap1.69B
Enterprise Value1.74B
Income24.41M
Sales156.94M
Book/sh0.23
Cash/sh0.13
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees160
IPOAug 08, 2013

Ratios

P/E105.59
Forward P/E7.64
PEG-
P/S10.78
P/B20.20
P/C36.73
P/FCF-
EV/EBITDA45.82
EV/Sales11.12
Quick Ratio4.83
Current Ratio5.58
Debt/Eq1.18
LT Debt/Eq1.16
Option/ShortYes / Yes

Earnings

EPS (ttm)0.04
EPS next Y0.62
EPS next Q0.11
EPS this Y117.15%
EPS next Y162.77%
EPS next 5Y-
EPS past 3/5Y-60.61% -6.02%
Sales past 3/5Y-28.87% -37.70%
EPS Y/Y TTM104.80%
Sales Y/Y TTM2387.61%
EPS Q/Q108.02%
Sales Q/Q2437.58%
EarningsNov 04 AMC
EPS/Sales Surpr.33.33% 3.63%

Ownership

Insider Own54.13%
Insider Trans-0.68%
Inst Own40.81%
Inst Trans2.14%
ROA12.73%
ROE38.84%
ROIC13.46%
Gross Margin90.61%
Oper. Margin21.43%
Profit Margin15.55%
SMA20-18.76%
SMA50-30.99%
SMA200-10.56%
Trades-

Technical

Shs Outstand358.54M
Shs Float164.47M
Short Float27.30%
Short Ratio7.67
Short Interest44.91M
52W High8.98 -47.44%
52W Low3.04 55.26%
Volatility12.24% 8.70%
ATR (14)0.54
RSI (14)35.70
Beta1.04
Rel Volume0.79
Avg Volume5.85M
Volume4,600,904

Performance

Perf Week-6.63%
Perf Month-36.90%
Perf Quarter-27.27%
Perf Half Y13.73%
Perf YTD12.92%
Perf Year19.19%
Perf 3Y333.03%
Perf 5Y8.26%
Perf 10Y-83.95%
Recom1.50
Target Price14.00
Prev Close4.52
Price4.72
Change %4.42%

Analyst ratings

latest 9 of 9
DateActionAnalystRating changeTargetImplied
Sep 25, 2026InitiatedRB. Riley SecuritiesBuy$12+154.2%
Aug 15, 2025UpgradeJJP MorganUnderweight → Neutral
Mar 22, 2024DowngradeJJP MorganNeutral → Underweight
May 23, 2023InitiatedJJP MorganNeutral
Nov 18, 2022InitiatedCCantor FitzgeraldOverweight$7+48.3%
Feb 25, 2021InitiatedSStifelBuy$13+175.4%
Feb 22, 2021InitiatedWWells FargoOverweight$14+196.6%
Feb 18, 2021InitiatedRB. Riley SecuritiesBuy$10+111.9%
May 08, 2020InitiatedHH.C. WainwrightBuy$5+5.9%

Peers

Mkt cap
TickerCompanyMkt cap
INOInovio Pharmaceuticals Inc152.51M
KRYSKrystal Biotech Inc9.15B
CGONCg Oncology Inc6.49B
CADLCandel Therapeutics Inc705.50M
PDSBPDS Biotechnology Corp107.11M
URGNUroGen Pharma Ltd1.28B
ABEOAbeona Therapeutics Inc131.44M
IOVAIovance Biotherapeutics Inc3.74B
RGNXRegenxbio Inc560.06M
VCELVericel Corp3.03B

Insider trading

latest 14 of 47
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Thomasian Harry Jr.Chief Financial OfficerSep 23 '26Option Exercise2.8153,665150,714311,914Sep 24 04:19 PM
KINDLER JEFFREY BDirectorAug 26 '26Sale7.44185,0001,376,40017,100Aug 28 08:39 PM
Jeffrey KindlerDirectorAug 26 '26Proposed Sale7.42185,0001,372,700Aug 26 04:43 PM
AGEE NANCY HDirectorAug 21 '26Buy7.233,41124,662309,187Aug 25 05:30 PM
Shah Rutul RChief Operating OfficerAug 21 '26Option Exercise2.3334,65880,753499,670Aug 25 05:27 PM
Shah Rutul RChief Operating OfficerAug 25 '26Option Exercise2.3315,34235,747484,207Aug 25 05:27 PM
Shah Rutul RChief Operating OfficerAug 21 '26Sale7.5034,658259,935465,012Aug 25 05:27 PM
Shah Rutul RChief Operating OfficerAug 25 '26Sale7.5015,342115,065468,865Aug 25 05:27 PM
Tennant PhilChief Commercial OfficerAug 25 '26Option Exercise1.6179,166127,457221,158Aug 25 05:25 PM
Tennant PhilChief Commercial OfficerAug 25 '26Sale7.5079,166593,745141,992Aug 25 05:25 PM
Shah Rutul ROfficerAug 25 '26Proposed Sale7.5015,342115,065Aug 25 02:01 PM
Tennant PhilOfficerAug 25 '26Proposed Sale7.5079,166593,745Aug 25 01:53 PM
Shah Rutul ROfficerAug 21 '26Proposed Sale7.5034,658259,935Aug 21 04:31 PM
Shah Rutul RChief Operating OfficerAug 06 '26Sale6.8632,739224,590465,012Aug 07 05:04 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
IBBiShares Biotechnology ETFAUM: 11.36B
VHTVanguard Health Care ETFAUM: 21.51B
GRNJFundstrat Granny Shots US Small & Mid-Cap ETFAUM: 408.20M
FYCFirst Trust Small Cap Growth AlphaDEX FundAUM: 1.35B

News

latest 14 of 200

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-040.0800.0600.10074.1571.553
2026Q22026-08-040.050-0.0120.04954.9827.983
2026Q12026-05-13-0.020-0.034-0.02223.2520.813
2025Q42026-03-25-0.072-0.084-0.0664.588.423
2025Q32025-11-13-1.060-0.094-1.0592.920.502
2025Q22025-08-13-0.090-0.087-0.0900.880.953
2025Q12025-05-14-0.180-0.130-0.1841.340.652
2024Q42025-03-19-0.074-0.053-0.0671.193.034
2024Q32024-11-14-0.090-0.086-0.0870.950.935
2024Q22024-08-14-0.230-0.096-0.2330.721.295
2024Q12024-05-14-0.100-0.088-0.0951.071.485
2023Q42024-03-19-0.130-0.079-0.1331.232.132
2023Q32023-11-09-0.080-0.080-0.0801.381.605
2023Q22023-08-09-0.080-0.101-0.0821.772.155
2023Q12023-05-10-0.100-0.093-0.0991.852.234
2022Q42023-03-06-0.110-0.100-0.1071.806.214

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-0.883-1.244-2.09190.72105.6
2020FY-1.020-0.843-1.025103.18100.88
2021FY-0.470-0.445-0.466103.87103.97
2022FY-0.400-0.395-0.33126.9157.87
2023FY-0.390-0.374-0.3926.237.13
2024FY-0.470-0.450-0.4723.935.80
2025FY-1.370-1.110-0.8559.6813.53
2026FY-0.235--242.41
2027FY-0.618--446.34
2028FY-0.927--584.05
2029FY-1.355--831.08
2030FY-1.455--999.92

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-0542289.0187.6090.45
2026Q4S2026-11-0440186.0566.40120
2026Q4S2026-10-2340186.0566.40120
2026Q4S2026-10-1940088.2566.40120
2026Q4S2026-09-2143088.2566.40120
2026Q4S2026-09-1833085.5366.40120
2026Q4S2026-08-0533085.5366.40120
2026Q4S2026-07-3130139.6534.9045.98
2026Q4S2026-07-2830139.6634.9046.00
2026Q4S2026-07-2432139.6634.9046.00
2026Q4S2026-06-1232139.6534.9045.98
2026Q4S2026-06-0132139.6334.9045.98
2026Q4S2026-05-2732139.6334.9045.98
2026Q4S2026-05-1432042.6334.9047.00

Estimate history

EPS, annual-0.975-3.932-2.091-1.025-0.466-0.331-0.392-0.472-1.3730.0447
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.087-0.067-0.184-0.09-1.059-0.066-0.0220.0490.085
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual230.981151.17890.722103.17814.26726.9096.2253.9259.684156.94
Period201720182019202020212022202320242025TTM
Sales, quarterly0.9531.191.3410.8562.9224.56523.25254.97874.148
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual122.087160.02163.275187.663206.74208.15248.919292.869353.911358.54
Period201720182019202020212022202320242025MRQ
Shares, quarterly292.869292.869295.135297.846353.811353.911355.904358.009358.54
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue156.949.683.926.2226.9114.27103.1890.72151.18
Cost of Goods Sold Incl. D&A14.746.107.3310.9711.1411.0255.5161.4062.68
Gross Profit142.203.59-3.40-4.7415.773.2547.6629.3288.50
Selling, General and Administrative Excl. Other108.57110.1991.3084.1890.3894.65133.35165.30492.00
Research and Development25.2740.0650.0148.6147.1747.9341.6466.67366.25
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income33.63-106.60-94.70-88.92-74.61-91.41-85.68-135.98-403.50
Interest Expense11.823.870.010.476.7718.7518.4017.678.47
Unusual Expense0.00143.4340.3210.780.160.540.9230.240.00
Net Income Before Taxes24.61-250.64-128.03-96.36-79.97-110.97-103.86-171.26-429.74
Income Taxes0.200.00-1.79-0.46-0.19-0.16-0.08-0.93-15.43
Consolidated Net Income24.41-250.64-126.23-95.90-79.78-110.81-103.77-170.33-414.32
Net Income From Continuing Operations24.41-250.64-126.23-95.90-79.78-110.81-103.77-168.74-408.95
Net Income24.41-429.64-126.23-95.90-66.39-92.17-171.19-322.32-509.34
EPS (Recurring)0.06-1.05-0.37-0.36-0.33-0.46-1.02-1.95-3.93
EPS (Basic, Before Extraordinaries)0.07-1.37-0.47-0.39-0.33-0.47-1.02-2.09-3.93
EPS (Diluted)0.04-1.37-0.47-0.39-0.33-0.47-1.02-2.09-3.93
EBITDA38.08-103.40-90.18-82.25-67.42-83.27-70.64-119.84-379.39
Non-Operating Income (Expense)2.793.267.013.801.57-0.261.1512.62-17.77
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense11.018.587.487.818.069.8912.4011.0225.61
Price To Earnings Ratio105.59105.59-------
Price To Sales Ratio22.97135.0976.4052.6411.3251.4316.529.315.60
Gross Margin90.6137.05-86.65-76.1858.6122.7746.2032.3258.54
Operating Margin21.43-1,100.78-2,412.87-1,428.48-277.25-640.67-83.04-149.89-266.90
Net Margin15.55-4,436.62-3,216.18-1,540.63-246.70-646.01-165.92-355.29-336.91
Shares Outstanding358.54353.91292.87248.92208.15206.74187.66163.27160.02
Market Capitalization1,692.361,692.36328.01333.55316.39767.001,822.57891.50897.43

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue74.1554.9823.254.572.920.861.341.19
Cost of Goods Sold Incl. D&A6.833.122.881.911.351.411.421.49
Gross Profit67.3251.8520.382.651.57-0.55-0.08-0.30
Selling, General and Administrative Excl. Other28.6729.2126.3724.3236.0527.3022.5222.44
Research and Development6.316.965.326.6712.0611.1710.1611.44
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income38.6522.64-5.99-21.67-34.48-27.86-22.60-22.74
Interest Expense3.002.952.912.960.900.000.00-
Unusual Expense0.000.000.000.00111.50-0.5532.485.78
Net Income Before Taxes35.9720.07-7.93-23.50-146.34-26.64-54.15-19.81
Income Taxes0.200.000.000.000.000.000.00-0.09
Consolidated Net Income35.7720.07-7.93-23.50-146.34-26.64-54.15-19.73
Net Income From Continuing Operations35.7720.07-7.93-23.50-146.34-26.64-54.15-19.73
Net Income35.7720.07-7.93-23.50-325.34-26.64-54.15-19.73
EPS (Recurring)0.080.05-0.02-0.07-0.81-0.09-0.11-0.05
EPS (Basic, Before Extraordinaries)0.100.06-0.02-0.07-1.06-0.09-0.18-0.07
EPS (Diluted)0.080.05-0.02-0.07-1.06-0.09-0.18-0.07
EBITDA39.7623.74-4.89-20.53-33.68-27.23-21.97-22.08
Non-Operating Income (Expense)0.310.380.971.130.540.670.938.70
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.983.313.011.714.391.292.682.26
Price To Earnings Ratio105.59-------
Price To Sales Ratio22.9727.5143.40152.76160.1896.99104.2383.57
Gross Margin90.7994.3287.6358.0753.70-64.72-5.82-24.96
Operating Margin52.1341.18-25.78-474.61-1,180.05-3,254.32-1,685.01-1,910.67
Net Margin48.2436.51-34.10-514.85-11,134.29-3,112.38-4,038.26-1,657.73
Shares Outstanding358.54358.01355.90353.91353.81297.85295.14292.87
Market Capitalization1,692.362,032.111,369.711,478.98980.33419.16438.12328.01

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments97.8697.9162.8599.29108.66100.1275.05223.8686.66
Short Term Receivables4.361.161.5713.801.9820.4326.2226.5739.84
Inventories9.580.000.000.290.3311.3616.1020.5720.49
Other Current Assets3.433.344.334.7845.6617.05117.2714.487.06
Total Current Assets115.23102.4168.75118.16156.63148.95234.64285.48154.05
Net Property, Plant & Equipment18.4418.8914.2115.4118.5944.2855.7686.90112.67
Total Investments and Advances2.510.000.270.4048.980.461.883.40190.40
Intangible Assets18.4123.5967.3181.3889.84119.76122.47182.59386.17
Deferred Tax Assets1.121.279.109.1716.009.7215.248.43-
Other Assets0.910.370.500.6345.811.1541.02157.813.56
Total Assets156.62146.54160.14225.15375.86324.31471.01724.61846.85
Short Term Debt Incl. Current Port. of LT Debt1.140.961.2044.431.453.0236.230.940.73
Accounts Payable11.983.531.734.073.194.625.5812.239.01
Other Current Liabilities24.1817.0320.0630.1530.0134.4981.1148.3970.42
Total Current Liabilities37.3121.5222.9878.6434.6542.13122.9161.5680.17
Long Term Debt97.154.555.896.99188.63179.27196.44211.227.54
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities1.121.2710.9511.4418.5412.6218.0812.2915.62
Other Liabilities0.1352.471.821.8226.7023.1261.8760.82196.98
Total Liabilities135.7179.8141.6498.89268.51257.13399.30345.88300.31
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.0028.220.000.000.000.000.000.000.00
Common Equity20.9138.51118.50126.26107.3567.1771.71362.86533.63
Total Shareholders Equity20.9166.73118.50126.26107.3567.1771.71362.86533.63
Accumulated Minority Interest0.000.000.000.000.000.000.0015.8712.91
Total Equity20.9166.73118.50126.26107.3567.1771.71378.72546.54
Total Liabilities & Stockholders Equity156.62146.54160.14225.15375.86324.31471.01724.61846.85
Book Value Per Share0.060.130.480.610.520.360.442.274.37
Tangible Book Value Per Share0.010.050.210.220.08-0.28-0.311.131.21
Full-Time Employees1601432022091911948578821,006
Price to Book Ratio20.205.922.332.227.1528.5012.482.882.60
Return on Assets-165.35-82.32-49.78-27.04-31.65-26.10-28.23-52.05-13.03
Return on Equity-571.97-136.30-78.37-68.30-126.98-149.44-77.66-91.23-21.40
Return on Invested Capital-212.29-177.10-77.10-49.82-31.14-69.47-120.20-88.72-21.62
Quick Ratio2.834.762.991.504.513.271.784.301.67
Current Ratio3.094.762.991.504.523.541.914.641.92

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income24.41-250.64-126.23-95.9028.32-92.17-170.52-323.92-514.71
Depreciation4.453.204.536.6710.7713.7617.5224.9033.11
Other Funds (Non Cash)12.96152.9952.6719.39-81.2823.6196.79164.34398.62
Funds from Operations41.81-94.45-70.83-70.33-42.35-54.97-56.37-138.36-104.25
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-115.026.622.663.40-22.70-0.80-20.652.43-19.98
Cash from Operating Activities-73.21-87.83-68.17-66.93-65.05-55.77-77.02-135.93-124.24
Capital Expenditures-1.10-2.00-8.58-1.54-4.92-7.25-7.53-37.88-41.59
Net Assets From Acquisitions0.000.000.000.000.000.000.00-10.96-17.50
Sale of Fixed Assets and Businesses0.000.000.060.10162.903.0170.720.8120.36
Purchase or Sale of Investments74.650.46-12.19-1.6568.44-74.05-38.36134.88-112.49
Purchase of Investments-173.90-208.01-187.21-185.030.00-174.22-171.36-55.07-178.68
Sale Or Maturity of Investments248.55208.47175.02183.3868.44100.17133.00189.9566.19
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.003.752.940.000.00
Cash from Investing Activities73.55-1.53-20.71-3.09226.42-74.5427.7886.85-151.21
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock2.650.31110.5872.810.00121.6535.126.9290.33
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock2.650.31110.5872.810.00121.6535.126.9290.33
Proceedsfrom Stock Options0.00-0.89110.2472.810.00121.0535.006.6187.99
Issuance or Reduction of Debt, Net-0.6592.820.00-43.22-155.29-0.47-2.411.21219.47
Change in Long Term Debt-0.6592.820.00-43.22-155.29-0.47-0.49-0.24219.24
Issuance of Long Term Debt-0.6592.820.000.000.000.000.000.38219.86
Reduction of Long Term Debt0.000.000.00-43.22-155.29-0.47-0.49-0.62-0.62
Net Financing Active Other Cash Flow-1.71-3.080.000.000.000.000.000.000.00
Other Financing Activities Uses-1.71-3.080.000.000.000.000.000.000.00
Cash from Financing Activities0.2990.05110.5829.59-155.29121.1932.708.14309.80
Exchange Rate Effect0.010.04-0.03-0.32-0.830.220.35-0.810.29
Net Change in Cash0.640.7221.67-40.755.25-8.91-16.18-41.7534.64
Free Cash Flow-74.32-89.83-76.76-68.47-69.97-63.02-84.55-173.81-165.83
Preferred Dividends (Cash Flow)--0.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.00-1.79-0.48-0.15-0.17-0.16-3.67-21.28

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments46.0738.2156.2597.86121.1459.75
Short Term Receivables96.6272.0426.704.361.100.57
Inventories22.9120.2514.729.583.060.00
Other Current Assets6.163.894.003.434.302.43
Total Current Assets171.76134.38101.67115.23129.6062.76
Net Property, Plant & Equipment17.3416.9417.5918.4419.6719.50
Total Investments and Advances4.910.490.492.512.510.00
Intangible Assets17.4617.7818.1018.4118.7319.05
Deferred Tax Assets---1.12--
Other Assets0.630.710.780.910.750.59
Total Assets212.10170.30138.63156.62171.26101.90
Short Term Debt Incl. Current Port. of LT Debt1.141.051.071.141.120.93
Accounts Payable7.065.302.5911.986.263.92
Other Current Liabilities22.6022.9917.4524.1824.6818.34
Total Current Liabilities30.7929.3521.1037.3132.0723.19
Long Term Debt97.4797.2997.1897.1597.074.22
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---1.12--
Other Liabilities0.050.080.110.130.2680.38
Total Liabilities128.31126.72118.39135.71129.40107.79
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.0030.88
Common Equity83.7943.5820.2320.9141.87-36.78
Total Shareholders Equity83.7943.5820.2320.9141.87-5.90
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity83.7943.5820.2320.9141.87-5.90
Total Liabilities & Stockholders Equity212.10170.30138.63156.62171.26101.90
Book Value Per Share0.230.120.060.060.12-0.12
Tangible Book Value Per Share0.190.070.010.010.07-0.19
Full-Time Employees---160--
Price to Book Ratio20.20100.2565.4935.32-26.64-29.81
Return on Assets12.73-115.88-152.89-165.35-193.82-142.24
Return on Equity38.84-837.08-1,145.42-571.97-507.72-668.03
Return on Invested Capital19.7314.25-6.75-19.91-105.33-
Quick Ratio4.833.894.122.833.952.71
Current Ratio5.584.584.823.094.042.71

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income35.7720.07-7.93-23.50-102.42-70.57
Depreciation1.111.101.101.140.800.63
Other Funds (Non Cash)3.983.733.511.7371.7244.56
Funds from Operations40.8624.91-3.32-20.63-29.90-25.38
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-28.97-42.71-40.51-2.830.836.40
Cash from Operating Activities11.88-17.81-43.83-23.46-29.07-18.98
Capital Expenditures-0.43-0.39-0.26-0.02-0.39-0.97
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-13.5427.0821.2339.88-63.0029.41
Purchase of Investments-68.50-47.66-33.87-23.86-145.27-28.47
Sale Or Maturity of Investments54.9674.7555.1063.7482.2757.88
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-13.9726.6920.9739.87-63.3928.44
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.00--0.00
Change in Capital Stock0.941.320.260.140.84-0.46
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.941.320.260.140.84-0.46
Proceedsfrom Stock Options0.000.000.000.000.00-0.54
Issuance or Reduction of Debt, Net0.000.000.00-0.6593.470.00
Change in Long Term Debt0.000.000.00-0.6593.470.00
Issuance of Long Term Debt0.000.000.00-0.6593.470.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.21-1.35-0.150.00-1.30-1.30
Other Financing Activities Uses-0.21-1.35-0.150.00-1.30-1.30
Cash from Financing Activities0.73-0.030.11-0.5193.01-1.77
Exchange Rate Effect-0.010.00-0.000.020.010.00
Net Change in Cash-1.378.85-22.7515.910.567.70
Free Cash Flow11.45-18.20-44.09-23.48-29.46-19.94

Revenue breakdown

United States2024: 3.93M 2025: 9.68M
Exemplar2024: 3.93M
Total Pharmaceutical Preparations revenue2025: 9.68M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3027.30%44.9M164.5M5.30M
2026-10-1528.25%46.4M164.2M5.02M
2026-09-3028.95%47.5M164.2M4.99M
2026-09-1525.73%42.3M164.3M4.86M
2026-08-3125.70%42.2M164.1M5.40M
2026-08-1425.77%42.2M163.9M5.20M
2026-07-3126.26%42.0M160.1M4.62M
2026-07-1525.76%41.0M159.3M4.45M
2026-06-3027.76%44.2M159.3M4.48M
2026-06-1527.26%43.3M159.0M4.65M
2026-05-2925.45%40.3M158.2M4.29M
2026-05-1525.16%39.9M158.5M4.56M
2026-04-3025.86%39.8M153.8M4.51M
2026-04-1525.88%39.8M153.8M4.68M
2026-03-3126.76%39.7M148.2M4.72M
2026-03-1326.85%39.8M148.2M4.63M
2026-02-2728.26%41.9M148.2M4.41M
2026-02-1327.73%41.1M148.2M4.40M
2026-01-3027.65%42.0M151.8M4.52M
2026-01-1525.96%39.4M151.8M4.66M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call1.002.904.100.0012.3580.000.000.972-0.0210.000
call2.002.003.202.037.8380.000.000.945-0.0200.001
call3.001.201.955.793.5031.000.000.907-0.0180.001
call4.000.051.050.752.31826113.000.823-0.0140.002
call5.000.150.250.161.2343,4863200.443-0.0240.003
call6.000.000.100.081.5096,6192340.184-0.0170.002
call7.000.000.050.021.7362,5720.000.093-0.0120.001
call8.000.000.350.152.1484,0130.000.079-0.0130.001
call9.000.000.300.042.4932,0540.000.071-0.0140.001
call10.000.000.100.042.7892,9101.000.065-0.0150.001
call11.000.000.100.133.0281,0630.000.062-0.0140.001
call12.000.000.300.003.2810.000.000.058-0.0160.001
call13.000.000.750.003.4890.000.000.056-0.0160.001
call14.000.000.750.113.6781.000.000.053-0.0170.001
call15.000.000.750.003.8520.000.000.052-0.0170.001
call16.000.000.750.004.0120.000.000.050-0.0170.001
call17.000.000.750.054.1606.000.000.049-0.0180.001
put1.000.000.250.057.5853.000.00-0.028-0.0200.000
put2.000.000.400.004.3890.000.00-0.055-0.0200.001
put3.000.000.750.002.6130.000.00-0.093-0.0180.001
put4.000.000.750.101.2952530.00-0.177-0.0140.002
put5.000.300.800.502.1782,3771.00-0.557-0.0230.003
put6.000.951.901.173.5276540.00-0.816-0.0160.002
put7.002.003.203.005.2868.000.00-0.907-0.0110.001
put8.002.804.001.825.1693.000.00-0.921-0.0120.001
put9.003.905.104.805.9931.000.00-0.929-0.0130.001
put10.004.906.104.106.3970.000.00-0.935-0.0140.001
put11.005.807.300.007.4470.000.00-0.939-0.0140.001
put12.006.708.200.007.4120.000.00-0.942-0.0150.001
put13.007.809.300.008.0400.000.00-0.944-0.0150.001
put14.008.7010.200.007.9430.000.00-0.947-0.0150.001
put15.009.7011.200.008.1730.000.00-0.948-0.0150.001
put16.0010.3012.700.0010.1130.000.00-0.950-0.0160.001
put17.0011.3013.700.0010.3100.000.00-0.951-0.0160.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-058-KCurrent report2026-11-04SEC
2026-11-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-09-244Statement of changes in beneficial ownership of securities2026-09-23SEC
2026-08-284Statement of changes in beneficial ownership of securities2026-08-26SEC
2026-08-26144Filing for proposed sale of securities under Rule 144.SEC
2026-08-25144Filing for proposed sale of securities under Rule 144.SEC
2026-08-25144Filing for proposed sale of securities under Rule 144.SEC
2026-08-254Statement of changes in beneficial ownership of securities2026-08-21SEC
2026-08-254Statement of changes in beneficial ownership of securities2026-08-23SEC
2026-08-254Statement of changes in beneficial ownership of securities2026-08-23SEC
2026-08-254Statement of changes in beneficial ownership of securities2026-08-21SEC
2026-08-254Statement of changes in beneficial ownership of securities2026-08-23SEC
2026-08-254Statement of changes in beneficial ownership of securities2026-08-23SEC
2026-08-21144Filing for proposed sale of securities under Rule 144.SEC
2026-08-07SCHEDULE 13G/ASEC
2026-08-074Statement of changes in beneficial ownership of securities2026-08-06SEC
2026-08-06144Filing for proposed sale of securities under Rule 144.SEC
2026-08-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-048-KCurrent report2026-08-04SEC
2026-08-03144Filing for proposed sale of securities under Rule 144.SEC
2026-08-034Statement of changes in beneficial ownership of securities2026-08-03SEC
2026-07-31144Filing for proposed sale of securities under Rule 144.SEC
2026-07-314Statement of changes in beneficial ownership of securities2026-07-31SEC
2026-07-01144Filing for proposed sale of securities under Rule 144.SEC
2026-07-014Statement of changes in beneficial ownership of securities2026-06-29SEC
2026-07-014Statement of changes in beneficial ownership of securities2026-06-29SEC
2026-07-014Statement of changes in beneficial ownership of securities2026-06-29SEC
2026-06-29144Filing for proposed sale of securities under Rule 144.SEC
2026-06-29144Filing for proposed sale of securities under Rule 144.SEC
2026-06-29144Filing for proposed sale of securities under Rule 144.SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-0824.66K12.79M6
2026-07001.55M2
2026-06002.46M3
2026-05001.15M5
2026-040000
2026-030015.75M1
2026-020000
2026-010000
2025-12008.80M2
2025-110012.29M3

Institutional holders

Manager% owned
Patient Capital Management, LLC5.34%
BlackRock, Inc.4.81%
STATE STREET CORP3.37%
Diametric Capital, LP2.60%
VANGUARD CAPITAL MANAGEMENT LLC2.22%
TANG CAPITAL MANAGEMENT LLC1.80%
Boxer Capital Management, LLC1.44%
GEODE CAPITAL MANAGEMENT, LLC1.42%
FMR LLC1.09%
Occam Crest Management LP1.01%

Funds

Fund% owned
Patient Opportunity Trust3.62%
State Street(R) SPDR(R) S&P(R) Biotech ETF1.99%
VANGUARD TOTAL STOCK MARKET INDEX FUND1.60%
iShares Russell 2000 ETF1.39%
Fidelity Small Cap Index Fund0.59%
VANGUARD EXTENDED MARKET INDEX FUND0.57%
iShares Russell 2000 Growth ETF0.50%
Fidelity Small Cap Growth Fund0.47%
First Trust Small Cap Growth AlphaDEX Fund0.43%
iShares Biotechnology ETF0.31%

OakChart. PGEN. Cached 15 minutes.